原发性胆汁性胆管炎健康相关生存质量量表及影响因素

杨娴; 唐映梅

doi:10.3969/j.issn.1001-5256.2020.09.050

原发性胆汁性胆管炎健康相关生存质量量表及影响因素

DOI: 10.3969/j.issn.1001-5256.2020.09.050

杨娴,
唐映梅

昆明医科大学第二附属医院消化内科

基金项目:

国家自然科学基金项目(81660102)；云南省科技厅科技计划项目(2018FE001)；

详细信息

中图分类号: R575.7
计量
- 文章访问数: 737
- HTML全文浏览量: 16
- PDF下载量: 126
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Health-related quality-of-life scales and related influencing factors in patients with primary biliary cholangitis

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University

Research funding:

摘要

摘要:
原发性胆汁性胆管炎(PBC)是一种自身免疫介导的慢性进行性肝病,后期可进展为肝硬化、肝癌,其临床表现及各种并发症使患者身心均受累,导致健康相关生存质量(HRQL)下降。当前人们对HRQL越来越重视,总结了国内外常用于评估PBC患者HRQL的量表,并分析了影响PBC患者HRQL的主要因素,以帮助临床更好地治疗及监测PBC患者。
- 肝硬化,胆汁性 /
- 生活质量 /
- 量表
Abstract:
Primary biliary cholangitis( PBC) is an autoimmune-mediated chronic progressive liver disease and can progress to liver cirrhosis and liver cancer in the late stage. Clinical manifestations and complications of PBC have significant impact on patients' mind and body,leading to the reduction in Health-related Quality of Life( HRQL). At present,HRQL has attracted more and more attention. This article summarizes the HRQL scales commonly used in China and foreign countries to assess HRQL in PBC patients and analyzes the main influencing factors for HRQL in PBC patients,in order to improve the treatment and monitoring of PBC patients in clinical practice.
- liver cirrhosis,biliary /
- quality of life /
- scale

HTML全文

参考文献(37)

[1] XU L,ZHENG YQ,SHI Z,et al. Influencing factors for the prognosis of primary biliary cholangitis[J]. J Clin Hepatol,2019,35(8):1870-1873.(in Chinese)徐黎，郑玥琪，时桢，等．原发性胆汁性胆管炎预后的影响因素[J]．临床肝胆病杂志，2019,35(8):1870-1873.

[2] HIRSCHFIELD GM,DYSON JK,ALEXANDER G,et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut,2018,67(9):1568-1594.

[3] KARIMI M,BRAZIER J. Health,Health-Related Quality of Life,and Quality of Life:What is the difference?[J]. Pharmacoeconomics,2016,34(7):645-649.

[4] WARE JE Jr,GANDEK B. Overview of the SF-36 health survey and the International Quality of Life Assessment(IQOLA)project[J]. J Clin Epidemiol,1998,51(11):903-912.

[5] ZHENG YB. Influencing factors of quality of life in hospitalized patients with chronic liver disease[J]. Guangxi Med J,2018,40(7):788-791.(in Chinese)郑亚彬．慢性肝病住院患者生存质量的影响因素研究[J]．广西医学，2018,40(7):788-791.

[6] GOLOVNOVA EV,LIU I,TSAREGORODTSEVA TM,et al. Primary biliary cirrhosis:12-year experience in observation[J].Ter Arkh,2003,75(2):26-30.

[7] RANNARD A,BUCK D,JONES DE,et al. Assessing quality of life in primary biliary cirrhosis[J]. Clin Gastroenterol Hepatol,2004,2(2):164-174.

[8] WONG GL,LAW FM,WONG VW,et al. Health-related quality of life in Chinese patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol,2008,23(4):592-598.

[9] JACOBY A,RANNARD A,BUCK D,et al. Development,validation,and evaluation of the PBC-40,a disease specific health related quality of life measure for primary biliary cirrhosis[J]. Gut,2005,54(11):1622-1629.

[10] WANG HT,REN LM,LIU Y,et al. Evaluation of SF-12 health survey scale[J]. Chin J Gen Pract,2015,14(7):574-576.(in Chinese)王海棠，任利民，刘瑶，等．SF-12健康调查量表的评价研究现状[J]．中华全科医师杂志，2015,14(7):574-576.

[11] WONG LL,FISHER HF,STOCKEN DD,et al. The impact of autoimmune hepatitis and its treatment on health utility[J].Hepatology,2018,68(4):1487-1497.

[12] WANG Z,LIU ZW,ZENG XY,et al. Health-related quality of life in patients with colorectal cancer precancerous lesions on EQ-5D-5L[J]. Pract Oncol J,2018,32(4):320-326.(in Chinese)王志，刘忠卫，曾雪芸，等．基于EQ-5D-5 L的结直肠癌癌前病变患者健康相关生命质量研究[J]．实用肿瘤学杂志，2018,32(4):320-326.

[13] LYU ZW,WANG QX,MA X. Assessment of the quality of life associated with autoimmune liver disease[J]. Int J Dig Dis,2019,39(2):73-76.(in Chinese)吕珠婉，王绮夏，马雄．自身免疫性肝病的健康相关生活质量评估[J]．国际消化病杂志，2019,39(2):73-76.

[14] YOUNOSSI ZM,KIWI ML,BOPARAI N,et al. Cholestatic liver diseases and health-related quality of life[J]. Am J Gastroenterol,2000,95(2):497-502.

[15] CHARATCHAROENWITTHAYA P,TALWALKAR JA,ANGULO P,et al. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J]. Dig Dis Sci,2010,55(2):476-483.

[16] ZEC S,POPOVIC D,MATOVIC V,et al. Translation and validation of the Serbian primary biliary cholangitis-40 questionnaire[J]. PLo S One,2017,12(4):e0175697.

[17] RASZEJA-WYSZOMIRSKA J,WUNSCH E,KRAWCZYK M,et al. Assessment of health related quality of life in polish patients with primary biliary cirrhosis[J]. Clin Res Hepatol Gastroenterol,2016,40(4):471-479.

[18] MILOVANOVIC T,POPOVIC D,STOJKOVIC LALOSEVIC M,et al. Quality of life in patients with primary biliary cholangitis:A single center experience in Serbia[J]. Dig Dis,2020.[Online ahead of print]

[19] KAPS L,GRAMBIHLER A,YEMANE B,et al. Symptom burden and treatment response in patients with primary biliary cholangitis(PBC)[J]. Dig Dis Sci,2019.[Online ahead of print]

[20] YAGI M,TANAKA A,ABE M,et al. Symptoms and healthrelated quality of life in Japanese patients with primary biliary cholangitis[J]. Sci Rep,2018,8(1):12542.

[21] ZHANG S,WANG L,ZHANG LL,et al. Analysis of the relationship between health-related quality of life(primary biliary cholangitis-40)and clinical presentations of patients with primary biliary cholangitis[J]. Chin J Rheumatol,2018,22(12):798-801.(in Chinese)张硕，王立，赵丽伶，等．原发性胆汁性胆管炎生活质量指标PBC-40与临床指标相关性分析[J]．中华风湿病学杂志，2018,22(12):798-801.

[22] KRAWCZYK M,KOZ'MA M,SZYMAN'SKA A,et al. Effects of liver transplantation on health-related quality of life in patients with primary biliary cholangitis[J]. Clin Transplant,2018,32(12):e13434.

[23] CARBONE M,MELLS GF,PELLS G,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology,2013,144(3):560-569. e7; quiz e13-e14.

[24] KHANNA A,JOPSON L,HOWEL D,et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis:A phase 2 randomized controlled trial[J]. Hepatology,2019,70(5):1646-1657.

[25] MONTALI L,TANAKA A,RIVA P,et al. A short version of a HRQo L questionnaire for Italian and Japanese patients with primary biliary cirrhosis[J]. Dig Liver Dis,2010,42(10):718-723.

[26] JONES D,PATANWALA I,NEWTON JL,et al. Comparison of the PBC-40 and PBC-27 tools for quality of life assessment in english speaking primary biliary cirrhosis patients[J]. Gut,2011:60(Suppl 1):a243.

[27] ALRUBAIY L,MELLS G,FLACK S,et al. PBC-10:A short quality of life measure for clinical screening in primary biliary cholangitis[J]. Aliment Pharmacol Ther,2019,50(11-12):1223-1231.

[28] ZAKHARIA K,TABIBIAN A,LINDOR KD,et al. Complications,symptoms,quality of life and pregnancy in cholestatic liver disease[J]. Liver Int,2018,38(3):399-411.

[29] KHANNA A,LEIGHTON J,LEE WONG L,et al. Symptoms of PBC-pathophysiology and management[J]. Best Pract Res Clin Gastroenterol,2018,34-35:41-47.

[30] JIN XY,KHAN TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus:A systematic review[J]. J Formos Med Assoc,2016,115(9):689-702.

[31] GOSSARD AA,LINDOR KD. Current and promising therapy for primary biliary cholangitis[J]. Expert Opin Pharmacother,2019,20(9):1161-1167.

[32] JOPSON L,JONES DE. Fatigue in primary biliary cirrhosis:Prevalence,pathogenesis and management[J]. Dig Dis,2015,33(Suppl 2):109-114.

[33] LEE JY,DANFORD CJ,TRIVEDI HD,et al. Treatment of fatigue in primary biliary cholangitis:A systematic review and meta-analysis[J]. Dig Dis Sci,2019,64(8):2338-2350.

[34] DE VLOO C,NEVENS F. Cholestatic pruritus:An update[J].Acta Gastroenterol Belg,2019,82(1):75-82.

[35] HEGADE VS,MELLS GF,FISHER H,et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom[J]. Clin Gastroenterol Hepatol,2019,17(7):1379-1387. e3.

[36] TRIVEDI HD,DANFORD CJ,GOYES D,et al. Osteoporosis in primary biliary cholangitis:Prevalence,impact and management challenges[J]. Clin Exp Gastroenterol,2020,13:17-24.

[37] DYSON JK,WILKINSON N,JOPSON L,et al. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis[J]. Aliment Pharmacol Ther,2016,44(10):1039-1050.

施引文献

资源附件(0)

访问统计